Weighing the benefits of high-dose simvastatin against the risk of myopathy

N Engl J Med. 2011 Jul 28;365(4):285-7. doi: 10.1056/NEJMp1106689. Epub 2011 Jun 15.

Authors

Amy Egan¹, Eric Colman

Affiliation

¹ Division of Metabolism and Endocrinology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.

PMID: 21675881
DOI: 10.1056/NEJMp1106689

No abstract available

MeSH terms

Anticholesteremic Agents / administration & dosage*
Anticholesteremic Agents / adverse effects
Creatine Kinase / blood
Drug Approval
Drug Interactions
Drug Labeling
Dyslipidemias / drug therapy*
Humans
Muscular Diseases / chemically induced*
Risk
Simvastatin / administration & dosage*
Simvastatin / adverse effects
United States
United States Food and Drug Administration

Substances

Anticholesteremic Agents
Simvastatin
Creatine Kinase